GSK stops Phase-II lupus trial

Share this article:

The 2012 Galapagos-GlaxoSmithKline alliance has been partly idled. Belgium-based Galapagos announced Monday that GSK has stopped Phase-II exploration of its JAK1 inhibitor GSK2586184 for systemic lupus erythematosus due to lack of effect.

Galapagos said that GSK has put an exploratory half-phase test of this same inhibitor in ulcerative colitis on hold.

Phase-II dosing in a third scenario—psoriasis—has wrapped and the company expects to provide top-line results in the first half of this year. This endpoint means GSK may cough up a milestone payment if results equal proof-of-concept.

Share this article:
You must be a registered member of MMM to post a comment.
close

Next Article in Business Briefs

The Women's Health landscape is ripe with opportunity for pharma marketers. This seven-page eBook offers product managers a guide to capitalizing on the trends, growth areas and unmet needs. Includes alternative channels to engage OB/GYNs and oncologists, and plenty of tips. Click here to access it.

Email Newsletters